Business Context and Reporting Period
Company: Evogene Ltd.
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2015
Accounting Standards: International Financial Reporting Standards (IFRS)
Business Overview: Evogene is an Israeli biotechnology company focused on improving crop productivity through seed traits, ag-chemicals, and ag-biologicals. The company operates primarily through strategic collaborations with major agricultural firms (e.g., Monsanto, Bayer, BASF) to fund research and development (R&D) in exchange for milestone payments and future royalties. It also operates a subsidiary, Evofuel, developing castor bean seeds for biofuel and industrial uses.
Key Financial Metrics (Year Ended Dec 31, 2015)
| Metric | 2015 (in thousands) | 2014 (in thousands) |
|---|---|---|
| Total Revenues | $11,129 | $14,511 |
| Cost of Revenues | $8,255 | $9,709 |
| Gross Profit | $2,874 | $4,802 |
| Operating Loss | $(17,921) | $(15,256) |
| Net Loss | $(17,213) | $(14,530) |
| Net Loss Per Share (Basic/Diluted) | $(0.68) | $(0.58) |
| Cash and Cash Equivalents | $10,221 | $5,213 |
| Marketable Securities | $71,807 | $80,040 |
| Total Current Assets | $104,376 | $118,371 |
| Total Liabilities | $8,843 | $11,504 |
| Working Capital | $98,737 | $110,452 |
| Shareholders' Equity | $103,752 | $116,082 |
Liquidity: As of December 31, 2015, the company held approximately $100.7 million in cash, marketable securities, and short-term bank deposits. Management believes these resources are sufficient to meet projected cash requirements for at least 12 months.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased by 23.3% ($3.4 million) from 2014 to 2015. This was primarily driven by a decrease in R&D payments due to amendments in collaboration work plans with Bayer and Syngenta.
- Increased Operating Loss: Operating loss widened by 17.5% to $17.9 million. While R&D expenses increased slightly (3.0%) due to expansion in self-funded activities (insect control, ag-chemicals, ag-biologicals) and share-based compensation, the revenue decline was the primary driver of the increased loss.
- Share Purchase Revenues: Revenues related to share purchases by collaborators (Monsanto and Bayer) dropped significantly to $0.2 million in 2015 from $0.3 million in 2014.
- Segment Performance: The Evogene segment (seed traits, ag-chemicals, ag-biologicals) generated all revenues ($11.1 million) but recorded an operating loss of $16.1 million. The Evofuel segment (castor seeds) recorded no revenue and an operating loss of $1.8 million.
Guidance, Outlook, and Risks
Outlook and Strategy:
- The company expects to continue incurring losses until products are commercialized and royalty revenues begin.
- Focus areas for 2016 include advancing existing collaborations, expanding ag-chemical operations (specifically the new collaboration with BASF for novel herbicides), and growing insect control and ag-biologicals activities.
- Evofuel entered its first commercial agreement for castor seed sales in early 2016, though revenues are not expected to be significant immediately.
Key Risks and Contingencies:
- Collaborator Concentration: Monsanto accounted for 77% of total revenues in 2015. Termination or non-renewal of the Monsanto agreement would have a material adverse effect.
- Commercialization Uncertainty: None of the company's discoveries have been commercialized. The product development cycle is lengthy (8-16 years for seed traits) and uncertain.
- Market Consolidation: Mergers in the seed and ag-chemical industry (e.g., Dow/DuPont, Syngenta/ChemChina) may limit the number of potential collaborators.
- Commodity Prices: Decreases in commodity prices (e.g., corn) may reduce collaborators' R&D budgets and subsequent payments to Evogene.
- Regulatory and Political Risks: Operations are subject to Israeli regulations and potential disruptions from regional conflicts. Additionally, regulatory approval for GM crops remains a significant hurdle in key markets.
- PFIC Status: There is a substantial risk the company may be classified as a Passive Foreign Investment Company (PFIC) for U.S. tax purposes in 2016, which could have adverse tax consequences for U.S. shareholders.
Investor Verification Checklist
- Revenue Concentration: Verify the status and renewal terms of the collaboration agreement with Monsanto, which generated 77% of 2015 revenues.
- Burn Rate vs. Cash: Confirm the runway of the $100.7 million cash position against the increasing operating losses (approx. $17.9 million in 2015) and capital expenditure plans.
- Collaboration Amendments: Review the specific terms of the amended work plans with Bayer and Syngenta that led to the 2015 revenue decline.
- PFIC Determination: Assess the likelihood of PFIC status for the 2016 tax year and its impact on U.S. investor tax liability.
- Evofuel Progress: Monitor the commercialization timeline and revenue potential of the castor bean seed business, which is currently pre-revenue.
- Intellectual Property: Evaluate the patent portfolio status for the 34 products currently under development.